Clinical potential of insulin therapy in critically ill patients

Drugs

Volumn 63, Issue 7, 2003, Pages 625-636

  Mesotten, Dieter ^a   Van Den Berghe, Greet ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

ACUTE KIDNEY FAILURE; ADAPTATION; ARTIFICIAL VENTILATION; BLOOD CLOTTING; CLINICAL TRIAL; COST CONTROL; CRITICAL ILLNESS; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN INFUSION; INSULIN TREATMENT; INTENSIVE CARE UNIT; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; POLYNEUROPATHY; REVIEW; SEPTICEMIA; STRESS; SURGICAL PATIENT;

CRITICAL CARE; CRITICAL ILLNESS; DIABETES COMPLICATIONS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INTENSIVE CARE UNITS; NUTRITIONAL SUPPORT; PROGNOSIS;

EID: 0037249582     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363070-00001     Document Type: Review

References (86)

1. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345 (19): 1359-67
2. Hill M, McCallum R. Altered transcriptional regulation of phosphoenolpyruvate carboxykinase in rats following endotoxin treatment. J Clin Invest 1991; 88 (3): 811-6
3. Khani S, Tayek JA. Cortisol increases gluconeogenesis in humans: its role in the metabolic syndrome. Clin Sci (Lond) 2001: 101 (6): 739-47
4. Watt MJ, Howlett KF, Febbraio MA, et al. Adrenaline increases skeletal muscle glycogenolysis, pyruvate dehydrogenase activation and carbohydrate oxidation during moderate exercise in humans. J Physiol 2001; 534 (Pt 1): 269-78
5. Flores EA, Istfan N, Pomposelli JJ, et al. Effect of interleukin-1 and tumor necrosis factor/cachectin on glucose turnover in the rat. Metabolism 1990; 39 (7): 738-43
6. Sakurai Y, Zhang XJ, Wolfe RR. TNF directly stimulates glucose uptake and leucine oxidation and inhibits FFA flux in conscious dogs. Am J Physiol 1996; 270 (5 Pt 1): E864-72
7. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992; 130 (1): 43-52
8. Damas P, Reuter A, Gysen P, et al. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989; 17 (10): 975-8
9. Van den Berghe G, Weekers F, Baxter RC, et al. Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness. J Clin Endocrinol Metab 2001; 86 (7): 3217-26
10. Cherrington AD. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 1999; 48 (5): 1198-214
11. Mizock BA. Alterations in carbohydrate metabolism during stress: a review of the literature. Am J Med 1995; 98 (1): 75-84
12. Mizock BA, Sugawara J, Tazuke SI, et al. Alterations in fuel metabolism in critical illness: hyperglycaemia. Best Pract Res Clin Endocrinol Metab 2001; 15 (4): 533-51
13. Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000; 355 (9206): 773-8
14. Boord JB, Graber AL, Christman JW, et al. Practical management of diabetes in critically ill patients. Am J Respir Crit Care Med 2001; 164 (10 Pt 1): 1763-7
15. Pozzilli P, Leslie RD. Infections and diabetes: mechanisms and prospects for prevention. Diabet Med 1994; 11 (10): 935-41
16. McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin 2001; 17 (1): 107-24
17. Van den Berghe G, de Zegher F, Bouillon R. Clinical review 95: acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab 1998; 83 (6): 1827-34
18. Van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 2003. In press
19. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329 (14): 977-86
20. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352 (9131): 837-53
21. Mukamal KJ. Nesto RW, Cohen MC, et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care 2001; 24 (8): 1422-7
22. Bolk J, van der Ploeg T, Cornel JH, et al. Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol 2001; 79 (2-3): 207-14
23. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26 (1): 57-65
24. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997; 314 (7093): 1512-5
25. Malmberg K, Ryden L, Hamsten A, et al. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J 1996; 17 (9): 1337-44
26. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997; 96 (4): 1152-6
27. Rovlias A, Kotsou S. The influence of hyperglycemia on neurological outcome in patients with severe head injury. Neurosurgery 2000; 46 (2): 335-42: discussion 42-3
28. Scott JF, Robinson GM, French JM, et al. Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycemia: the Glucose Insulin in Stroke Trial (GIST). Stroke 1999; 30 (4): 793-9
29. Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 2001; 109 Suppl. 2: S424-37
30. Nissenson AR. Acute renal failure: definition and pathogenesis. Kidney Int Suppl 1998; 66: S7-10
31. Murray P, Hall J. Renal replacement therapy for acute renal failure. Am J Respir Crit Care Med 2000; 162 (3 Pt 1): 777-81
32. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 1995; 47 (6): 1703-20
33. Boulton AJ. Clinical presentation and management of diabetic neuropathy and foot ulceration. Diabet Med 1991; 8: S52-7
34. Boulton AJ, Malik RA. Diabetic neuropathy. Med Clin North Am 1998; 82 (4): 909-29
35. Vinik AI, Park TS, Stansberry KB, et al. Diabetic neuropathies. Diabetologia 2000; 43 (8): 957-73
36. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122 (8): 561-8
37. Hund E. Neurological complications of sepsis: critical illness polyneuropathy and myopathy. J NeuroI 2001; 248 (11): 929-34
38. Leijten FS, De Weerd AW, Poortvliet DC, et al. Critical illness polyneuropathy in multiple organ dysfunction syndrome and weaning from the ventilator. Intensive Care Med 1996; 22 (9): 856-61
39. Bolton CF, Young GB. Critical illness polyneuropathy. Curr Treat Options Neurol 2000; 2 (6): 489-98
40. Bolton CF. Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med 1996; 24 (8): 1408-16
41. Nielson CP, Hindson DA. Inhibition of polymorphonuclear leukocyte respiratory burst by elevated glucose concentrations in vitro. Diabetes 1989; 38 (8): 1031-5
42. Kwoun MO, Ling PR, Lydon E, et al. Immunologic effects of acute hyperglycemia in nondiabetic rats. J Parenter Enteral Nutr 1997; 21 (2): 91-5
43. Rassias AJ, Marrin CA, Arruda J, et al. Insulin infusion improves neutrophil function in diabetic cardiac surgery patients. Anesth Analg 1999; 88 (5): 1011-6
44. Rayfield EJ, Ault MJ, Keusch GT, et al. Infection and diabetes: the case for glucose control. Am J Med 1982; 72 (3): 439-50
45. Rassias AJ, Givan AL, Marrin CA, et al. Insulin increases neutrophil count and phagocytic capacity after cardiac surgery. Anesth Analg 2002; 94 (5): I113-9
46. Zerr KJ, Furnary AP, Grunkemeier GL, et al. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 1997; 63 (2): 356-61
47. Furnary AP, Zerr KJ, Grunkemeier GL, et al. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999; 67 (2): 352-60; discussion 60-2
48. Gore DC, Chinkes D, Heggers J, et al. Association of hyperglycemia with increased mortality after severe burn injury. J Trauma 2001; 51 (3): 540-4
49. Taskinen MR. Pathogenesis of dyslipidemia in type 2 diabetes. Exp Clin Endocrinol Diabetes 2001; 109 Suppl. 2: S180-8
50. Fong DG, Nehra V, Lindor KD, et al. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 2000; 32 (1): 3-10
51. Hall RI, Grant JP, Ross LH, et al. Pathogenesis of hepatic steatosis in the parenterally fed rat. J Clin Invest 1984; 74 (5): 1658-68
52. Klein S, Peters EJ, Shangraw RE, et al. Lipolytic response to metabolic stress in critically ill patients. Crit Care Med 1991; 19 (6): 776-9
53. Lopez-Martinez J, Sanchez-Castilla M, Garcia-de-Lorenzo A. Hypocholesterolemia in critically ill patients. Intensive Care Med 2000; 26 (2): 259-60
54. Giovannini I, Boldrini G, Chiarla C, et al. Pathophysiologic correlates of hypocholesterolemia in critically ill surgical patients. Intensive Care Med 1999; 25 (7): 748-51
55. Harris HW, Johnson JA, Wigmore SJ. Endogenous lipoproteins impact the response to endotoxin in humans. Crit Care Med 2002; 30 (1): 23-31
56. Gordon BR, Parker TS, Levine DM, et al. Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia. Crit Care Med 1996; 24 (4): 584-9
57. Khovidhunkit W, Memon RA, Feingold KR, et al. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000; 181 Suppl. 3: S462-72
58. Carpentier YA, Scruel O. Changes in the concentration and composition of plasma lipoproteins during the acute phase response. Curr Opin Clin Nutr Metab Care 2002; 5 (2): 153-8
59. Hansen TK, Thiel S, Wouters PJ, et al. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-bonding lectin levels. J Clin Endocrinol Metab 2003. In press
60. Das UN. Is insulin an antiinflammatory molecule? Nutrition 2001; 17 (5): 409-13
61. Satomi N, Sakurai A, Haranaka K. Relationship of hypoglycemia to tumor necrosis factor production and antitumor activity: role of glucose, insulin, and macrophages. J Natl Cancer Inst 1985; 74 (6): 1255-60
62. Fraker DL, Merino MJ, Norton JA. Reversal of the toxic effects of cachectin by concurrent insulin administration. Am J Physiol 1989; 256 (6 Pt 1): E725-31
63. Sakaue S, Nishihira J, Hirokawa J, et al. Regulation of macrophage migration inhibitory factor (MIF) expression by glucose and insulin in adipocytes in vitro. Mol Med 1999; 5 (6): 361-71
64. Chen HC, Guh JY, Shin SJ, et al. Insulin and heparin suppress superoxide production in diabetic rat glomeruli stimulated with low-density lipoprotein. Kidney Int Suppl 2001; 78: S124-7
65. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001; 15 (1): 44-54
66. Calles-Escandon J, Garcia-Rubi E, Mirza S, et al. Type 2 diabetes: one disease, multiple cardiovascular risk factors. Coron Artery Dis 1999; 10 (1): 23-30
67. Williams E, Timperley WR, Ward JD, et al. Electron microscopical studies of vessels in diabetic peripheral neuropathy. J Clin Pathol 1980; 33 (5): 462-70
68. Patrassi GM, Vettor R, Padovan D, et al. Contact phase of blood coagulation in diabetes mellitus. Eur J Clin Invest 1982; 12 (4): 307-11
69. Carmassi F, Morale M, Puccetti R, et al. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 1992; 67 (6): 643-54
70. Hughes A, McVerry BA, Wilkinson L, et al. Diabetes, a hypercoagulable state?. Hemostatic variables in newly diagnosed type 2 diabetic patients. Acta Haematol 1983; 69 (4): 254-9
71. Garcia Frade LJ, de la Calle H, Alava I, et al. Diabetes mellitus as a hypercoagulable state: its relationship with fibrin fragments and vascular damage. Thromb Res 1987; 47 (5): 533-40
72. Vukovich TC, Schernthaner G. Decreased protein C levels in patients with insulin-dependent type I diabetes mellitus. Diabetes 1986; 35 (5): 617-9
73. Bick RL. Disseminated intravascular coagulation: a review of etiology, pathophysiology, diagnosis, and management: guidelines for care. Clin Appl Thromb Hemost 2002; 8 (1): 1-31
74. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344 (10): 699-709
75. Garcia Frade LJ, Landin L, Avello AG, et al. Changes in fibrinolysis in the intensive care patient. Thromb Res 1987; 47 (5): 593-9
76. Mavrommatis AC, Theodoridis T, Economou M, et al. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock. Intensive Care Med 2001; 27 (12): 1853-9
77. Schloerb PR, Henning JF. Patterns and problems of adult total parenteral nutrition use in US academic medical centers. Arch Surg 1998; 133 (1): 7-12
78. Klein CJ, Stanek GS, Wiles III CE. Overfeeding macronutrients to critically ill adults: metabolic complications. J Am Diet Assoc 1998; 98 (7): 795-806
79. McCowen KC, Friel C, Sternberg J, et al. Hypocaloric total parenteral nutrition: effectiveness in prevention of hyperglycemia and infectious complications: a randomized clinical trial. Crit Care Med 2000; 28 (11): 3606-11
80. Patino JF, de Pimiento SE, Vergara A, et al. Hypocaloric support in the critically ill. World J Surg 1999; 23 (6): 553-9
81. Choban PS, Burge JC, Scales D, et al. Hypoenergetic nutrition support in hospitalized obese patients: a simplified method for clinical application. Am J Clin Nutr 1997; 66 (3): 546-50
82. Landstedt-Hallin L, Englund A, Adamson U, et al. Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med 1999; 246 (3): 299-307
83. Pollock G, Brady Jr WJ, Hargarten S, et al. Hypoglycemia manifested by sinus bradycardia: a report of three cases. Acad Emerg Med 1996; 3 (7): 700-7
84. Chelliah YR. Ventricular arrhythmias associated with hypoglycaemia. Anaesth Intensive Care 2000; 28 (6): 698-700
85. Van den Berghe G, Bouillon R, Lauwers P. Intensive insulin therapy in critically ill patients [letter]. N Engl J Med 2002; 346 (20): 1586-8
86. Mesotten D, Delhanty PJD, Vanderhoydonc F, et al. Regulation of insulin-like growth factor binding protein-1 during protracted critical illness. J Clin Endocrinol Metab 2002 Dec; 87 (12): 5516-23